top of page

Regorafenib increases overall survival in hepatocellular carcinoma study

Results from the Phase III RESORCE trial investigatingBayer’s regorafenib in patients with unresectable hepatocellular carcinoma (HCC) who progressed during treatment with sorafenib (Nexavar) tablets have been announced.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page